Study first to evaluate prevalence, impact of off label chemotherapy in breast cancer

At some point during their care, more than one-third of metastatic breast cancer patients receive chemotherapy off label, the legal use of FDA-approved drugs in a different indication than for which they were approved, according to researchers at The University of Texas M. D. Anderson Cancer Center.

Read the whole article on Physorg

More from Physorg